Zai Lab Ltd

ZLAB

NASDAQ. Currency in USD

34.20 -0.88 ( -2.51% )

Real time prices: September 30

Market Cap.
3.35B
Beta (5Y monthly)
1.00
Price/Earnings
-
EPS (TTM)
-5.55
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
480,442
1y Target Est.
191.87
Day's Range
33.50
-
36.18
52 Week's Range
22.51
-
107.98

Historical Summary

Performance
EPS growth
Share Buybacks

About Zai Lab Ltd

Sector
Healthcare
Industry
Biotechnology
Website
https://www.zailaboratory.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
97.91M
Employees
1951
Address
Jinchuang Plaza, Shanghai, China, 201210
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Latest news

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug...
By GlobeNewswire Inc. - 5 days ago

KB Home, Darden Restaurants And Other Big Losers From Thursday
KB Home, Darden Restaurants And Other Big Losers From Thursday

U.S. stocks closed lower with the Dow Jones dropping more than 100 points on Thursday....
By Benzinga - 1 week ago

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) shares jumped 167.7% to close at $2.20 on Thursday...
By Benzinga - 1 week ago

Chemours, Alcoa And Other Big Losers From Wednesday
Chemours, Alcoa And Other Big Losers From Wednesday

U.S. stocks closed lower with the Dow Jones dropping more than 500 points on Tuesday....
By Benzinga - 1 week ago

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday

Gainers Stabilis Solutions, Inc. (NASDAQ: SLNG) shares climbed 71.3% to close at $8.84 after the...
By Benzinga - 1 week ago

Kroger, DocuSign And Other Big Gainers From Friday
Kroger, DocuSign And Other Big Gainers From Friday

U.S. stocks closed higher with the Nasdaq Composite surging 250 points on Friday. Here is...
By Benzinga - 2 weeks ago

Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on...
By Benzinga - 3 weeks ago